BioXcel Therapeutics, Inc. Common Stock

BTAI XNAS • PHARMACEUTICAL PREPARATIONS

Historical Short Interest Share

Chase Ink Business Preferred®

Earn Up to 150K Bonus Points

Transfer points to 14+ airline & hotel partners. Up to 40% upgrade value on first class travel. $95/yr.

Apply Now

Market Cap

37M

Short interest (May 15)

13.1%

Net Short (Jun 03 ): 0.1%

Borrow Fee

4.92%

↓ 5.9%

Available Shares

500K

↓ 17.4%

Price Chart

Company Overview

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

Company Info

Exchange: NASDAQ

Industry: PHARMACEUTICAL PREPARATIONS

CIK: 0001720893

Asset Type: CS

Market Data

Market Cap: $36,744,349

Employees: 29

Status: Active

Short Interest

Current Borrow Fee 4.92%

Range: 4.92% - 5.09%

Available Shares 500K

Range: 150K - 550K

Recent Changes

Fee Change: ↓ 0.8%

Available Change: ↓ 25.0%

Quick Actions

View Dilution Chart

Add to Watchlist Set Price Alert View Options Chain

Investment Risk

This is not financial advice. All investments carry risk. Do your own research before making investment decisions.

Weekly Research

Get Weekly Super Stonk Alerts

Never miss a squeeze opportunity. Get our weekly analysis of high short interest stocks, AI-discovered gems, and dilution warnings delivered to your inbox.

No spam • Unsubscribe anytime